⌕
Alexion Pharmaceuticals · ALXN · Nasdaq
$182.50at last closeTenet 64 · Solid
Compare
$182.50at last closeTenet 64 · Solid

Alexion Pharmaceuticals (ALXN) Key Ratios

Valuation, quality, health and growth. Every ratio ranked against its sector peers — the number we score — with its own ten-year record shown beside it for context.

Sources Company filings and market prices Filings and pricesRatios computed How we compute thisNot investment advice
40
VALUE
Fairly priced
in line with its peers
75
QUALITY
Elite
top-decile economics
59
HEALTH
Stable
manageable balance sheet
83
GROWTH
FCF only
growth rates not measurable; scored on FCF margin alone

An elite business at a fair price: value 40, quality 75, health 59, growth 83, each a percentile within Healthcare.

track = where peers land, worse → better (direction-adjusted: right always means better)▏sector median● you are here▲ where today's value sits in the company's own 10-year record (context, not scored)hover any metric for its formula
40th pctilein line with its peers
Earnings yield (EBIT/EV)EBIT (operating income) for the latest fiscal year ÷ enterprise value on the current market cap (Greenblatt). The vendor's own earnings yield is net income to common ÷ market cap, a different figure.1.6%16th pctile
P/E57.518th pctile
P/B3.070th pctile
P/FCF14.078th pctile
EV / EBITDA36.019th pctile
59th pctilemanageable balance sheet
Current ratio3.5952nd pctile
Quick ratio(Cash, short-term investments and receivables) ÷ current liabilities, as the data vendor builds it. Its receivables include non-trade receivables, which Tenet's balance sheet shows inside other current assets.2.7149th pctile
Net debt / EBITDADebt less cash and all investments, including long-term stakes, over EBITDA, as the data vendor builds it−0.2×76th pctile
Interest coverage6.0×50th pctile
Debt / equity0.2568th pctile
75th pctiletop-decile economics
ROIC—Not reported in the company's filings for this period.
ROE5%65th pctile
Gross margin90.9%78th pctile
Net margin9.9%79th pctile
Income quality (CFO/NI)4.98×96th pctile
Piotroski F6 / 974th pctileown record too short
Altman Z4.456th pctile
83rd pctilegrowth rates not measurable; scored on FCF margin alone
Revenue CAGRThe yearly rate that compounds the earliest fiscal year's revenue into the latest one, over the true number of fiscal years between them (up to five). When the earliest year's revenue is zero or negative, the rate starts from the first later year with at least $10M of revenue, provided at least three years remain.—This growth figure starts in a period outside the history your plan includes.
EPS CAGR—This growth figure starts in a period outside the history your plan includes.
FCF margin47.7%97th pctile
the receipts behind the numbers above
Greenblatt earnings yield1.6%EBIT ÷ EV The vendor's "earningsYield" is NI ÷ market cap, which is not Greenblatt's formula.
ROIC—NOPAT ÷ invested capital The vendor's simple ROIC, not its tiny-base roic tag; withheld when a negative EBIT flips its sign.
Interest coverage6.0× EBIT ÷ interest expense, ranked within sector peers.
Percentiles computed nightly against 374 Healthcare peers from our ingested fundamentals DB · raw statements for corrected metrics. Direction-adjusted: for "lower is better" ratios (P/E, D/E…) the percentile is flipped so right always means better. The percentile is the stock's rank among sector peers, the number that is scored. The triangle marks where the current value sits in the company's own ten-year annual record, shown for context and never blended into the score. Computed Jul 29, 2026 · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.